Cara-lin Lonetree

University of Minnesota — United States

Medicine · Health Sciences

9h-index982citations30works0.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(20), Cancer Immunotherapy and Biomarkers(13), Immune Cell Function and Interaction(12), CRISPR and Genetic Engineering(10), Virus-based gene therapy research(6)

Publications30 total

IL-15 complex with agonistic anti-CD40 + anti-PDL1 overcomes T cell exhaustion and drives a T-bet+ effector program for pancreatic ductal adenocarcinoma eradication 3573
The Journal of Immunology·2025Open Access
Targeting Regulatory T cells controls metastatic pancreatic ductal adenocarcinoma by modulation of conventional CD4 T helper cells 3557
The Journal of Immunology·2025Open Access
A Singular Base Editing Platform for Polyfunctional Multiplex Engineering of Immune Cells
2025· 1 citedOpen Access
Supplementary Figure 6 from IL-15 Complex Enhances Agonistic Anti-CD40 + Anti-PDL1 by Correcting the T-bet to Tox Ratio in CD8<sup>+</sup> T cells Infiltrating Pancreatic Ductal Adenocarcinoma
2025Open Access
Supplementary Figure 1 from IL-15 Complex Enhances Agonistic Anti-CD40 + Anti-PDL1 by Correcting the T-bet to Tox Ratio in CD8<sup>+</sup> T cells Infiltrating Pancreatic Ductal Adenocarcinoma
2025Open Access
Data from IL-15 Complex Enhances Agonistic Anti-CD40 + Anti-PDL1 by Correcting the T-bet to Tox Ratio in CD8<sup>+</sup> T cells Infiltrating Pancreatic Ductal Adenocarcinoma
2025· 1 citedOpen Access
Supplementary Tables from IL-15 Complex Enhances Agonistic Anti-CD40 + Anti-PDL1 by Correcting the T-bet to Tox Ratio in CD8<sup>+</sup> T cells Infiltrating Pancreatic Ductal Adenocarcinoma
2025Open Access
Supplementary Figure 3 from IL-15 Complex Enhances Agonistic Anti-CD40 + Anti-PDL1 by Correcting the T-bet to Tox Ratio in CD8<sup>+</sup> T cells Infiltrating Pancreatic Ductal Adenocarcinoma
2025Open Access
Supplementary Figure 7 from IL-15 Complex Enhances Agonistic Anti-CD40 + Anti-PDL1 by Correcting the T-bet to Tox Ratio in CD8<sup>+</sup> T cells Infiltrating Pancreatic Ductal Adenocarcinoma
2025Open Access
Supplementary Figure 2 from IL-15 Complex Enhances Agonistic Anti-CD40 + Anti-PDL1 by Correcting the T-bet to Tox Ratio in CD8<sup>+</sup> T cells Infiltrating Pancreatic Ductal Adenocarcinoma
2025Open Access
Supplementary Figure 9 from IL-15 Complex Enhances Agonistic Anti-CD40 + Anti-PDL1 by Correcting the T-bet to Tox Ratio in CD8<sup>+</sup> T cells Infiltrating Pancreatic Ductal Adenocarcinoma
2025Open Access
Supplementary FIgure 8 from IL-15 Complex Enhances Agonistic Anti-CD40 + Anti-PDL1 by Correcting the T-bet to Tox Ratio in CD8<sup>+</sup> T cells Infiltrating Pancreatic Ductal Adenocarcinoma
2025Open Access
Supplementary Figure 4 from IL-15 Complex Enhances Agonistic Anti-CD40 + Anti-PDL1 by Correcting the T-bet to Tox Ratio in CD8<sup>+</sup> T cells Infiltrating Pancreatic Ductal Adenocarcinoma
2025Open Access
Supplementary Figure 5 from IL-15 Complex Enhances Agonistic Anti-CD40 + Anti-PDL1 by Correcting the T-bet to Tox Ratio in CD8<sup>+</sup> T cells Infiltrating Pancreatic Ductal Adenocarcinoma
2025Open Access
IL-15 Complex Enhances Agonistic Anti-CD40 + Anti-PDL1 by Correcting the T-bet to Tox Ratio in CD8+ T cells Infiltrating Pancreatic Ductal Adenocarcinoma
Cancer Immunology Research·2025· 4 citedOpen Access
Abstract 5308: Ifngr1 signaling on tumor-specific CD4 T cells is required to mitigate Treg differentiation during CD40 agonist and anti-PD-L1 immunotherapy in pancreatic ductal adenocarcinoma
Cancer Research·2024
A Pan-RNase Inhibitor Enabling CRISPR-mRNA Platforms for Engineering of Primary Human Monocytes
International Journal of Molecular Sciences·2022· 4 citedOpen Access
CRISPR-Cas9 cytidine and adenosine base editing of splice-sites mediates highly-efficient disruption of proteins in primary and immortalized cells
Nature Communications·2021· 111 citedOpen Access
CRISPR-Cas9 cytidine and adenosine base editing of splice-sites mediates highly-efficient disruption of proteins in primary cells
2020· 4 citedOpen Access
Author Correction: Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editors
Nature Communications·2019· 9 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Zoe C. Schmiechen(15), Adam L. Burrack(15), Eduardo Cruz-Hinojoza(15), Ebony A. Miller(15), Ingunn M. Stromnes(15), Grant H. Hickok(14), Jonah Z. Butler(14), Alexander K. Tsai(14), Beau R. Webber(13), Hezkiel A. Nanda(13), Nicholas J. Maurice(13), A. Rizzo(13), Steven S. Shen(13), Michael J. Geuenich(12), Chengxin Yu(12), Madeline A. Ellefson(12), Audrey L. Hilk(12), Brandon M. Larsen(12), Kieran R. Campbell(12), Walker S. Lahr(9)